Incyte vs Insmed

Incyte (INCY), health care, and Insmed (INSM), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Insmed is worth $26.7B on the stock market and Incyte $24.3B: Insmed is valued at 10% more. Incyte's operating margin in its latest fiscal year was 29.5% and Insmed's -206%. Over the past year Incyte's share price has moved +15.8% and Insmed's -39.1%.

Key facts

Incyte market value
$24.3B
Insmed market value
$26.7B
Incyte P/E
61.4
Incyte revenue
$5.1BFY to 2025-12-31
Insmed revenue
$606.4MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Incyte vs Insmed: every measure side by side
Measure Incyte Insmed
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$24.3Blower$26.7Bhigher
Revenue$5.1Bhigher$606.4Mlower
Earnings$1.3Bhigher-$1.3Blower
Employees2,844higher1,664lower
Total assets$7Bhigher$2.3Blower
Valuation
P/E61.4—
P/S4.7lower44.1higher
P/B4.3lower36.8higher
Dividend yield0.00%0.00%
Profitability
Operating margin29.5%higher-206%lower
Balance sheet
Net assets$5.2Bhigher$739Mlower
Total liabilities$1.8Bhigher$1.5Blower
Total debt—$546.8M
Cash on hand$3.1Bhigher$510.4Mlower
Price change
Today-0.98%lower-0.83%higher
1 year+15.8%higher-39.1%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Incyte / Insmed). Who owns INCY · Who owns INSM

Further comparisons

Learn

Questions and answers

Which is bigger, Incyte or Insmed?

By market value, Insmed is the larger: $26.7B against $24.3B for Incyte. By revenue in its latest fiscal year, Incyte is the larger: $5.1B against $606.4M for Insmed.

Which has the higher operating margin?

Incyte: 29.5%, against -206% for Insmed. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Incyte and Insmed?

In their latest 13F filings, Julian and Felix Baker holds both.

Cite this page

Funkfolio, “Incyte vs Insmed”, data as of 18 November 2026. https://funkfolio.com/compare/incy-vs-insm

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.